Citi Credit Research Sees Opportunity in Valeant (VRX), Initiates With Overweight Rating (MNK) (ENDP)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Left for Dead Valeant Pharma (VRX) Is Up 30% In a Week
November 23, 2015 10:43 AM ESTShort seller target Valeant Pharma (NYSE: VRX) is continuing to rally sharply off oversold conditions following a few modest positives over the past week or so:
Citi launched coverage on the... MoreGuggenheim Remains Positive on Mallinckrodt (MNK) Post 4Q Beat
November 23, 2015 10:37 AM ESTGuggenheim maintained a Buy rating and $130.00 price target on Mallinckrodt plc (NYSE: MNK) following the company's 4Q earnings report. MNK reported F4Q15 EPS of $1.84, $0.09 higher than consensus. Management reaffirmed its F'16 EPS guidance of $7.70 to $8.20 compared to consensus of $7.91.
Analyst Louise... More
Valeant Pharma (VRX) Adds to Strong Gains; Sets Sights on $90
November 20, 2015 1:10 PM ESTShort seller target Valeant Pharma (NYSE: VRX) is seeing notably strength again today on the back of yesterday's 16% move up. Shares last traded up 5.6% to $88.73.
Yesterday, Citi endorsed the credit with an Overweight rating and today Mizuho reiterated it as a top pick, saying "the stock appears to have bottomed."
... MoreValeant Pharma (VRX) to Host December 16 Investor Day
November 20, 2015 9:00 AM ESTShort seller target Valeant Pharma (NYSE: VRX) announced it will will be hosting an Investor Day on December 16, 2015 where the Company will be providing updated financial guidance, discussing certain business operations and highlighting certain R&D programs.
Conference Call and Webcast... More
Valeant Pharmaceuticals (VRX) Reiterated Top Pick at Mizuho Securities; PT to $111
November 20, 2015 6:36 AM ESTMizuho Securities analyst Irina Koffler reiterated Valeant Pharmaceuticals (NYSE: VRX) as their Top Pick while maintaining an Outperform rating and lowering thier price target to $111.00 (from $155.00).
The analyst highlighted:
The stock appears to have bottomed, in our view: We are by no means ignoring the risks tied to this stock. We worry about expansion of existing investigations, congressional probes of Philidor, and potential changes to senior management. All that said, we believe that the risk/reward in VRX is still favorable given business fundamentals. We are primarily... MoreValeant Pharma (VRX) Surges as Co's Debt Gets Endorsed
November 19, 2015 10:05 AM ESTBeaten down Valeant Pharma (NYSE: VRX) is up 9% early to $79, benefiting from today's Overweight rating on the company's debt at Citi.
The firm cited product diversification and strong FCF generation.
... More